Drugs in the pipeline: new therapies that could change treatment ...(r immune cells that carry a mutation in ...),Health
r immune cells that carry a mutation in the receptor protein Fc?RIIIa 158-F do not have the same response, Forero says. This is an issue that is related to the patients own biological makeup, not to the cancer cells themselves, he adds. There are three different classes of Fc? receptors to which the monoclonal antibody binds on leukocyte effector cells T helper cells -- that direct other immune cells to the antigen. Response to rituximab depends on variants in the receptors these helper cells use.
AME-133v is an anti-CD20 antibody engineered to bind more strongly to these variant receptors. In preclinical studies, it demonstrated a 10-fold improved killing power of human B cells, compared with rituximab, researchers report.
Of the 22 patients treated with AME-133v in this study, 20 had been treated with rituximab and 18 also had chemotherapy. All were Fc?RIIIa 158-F carriers. This was a dose escalation study, and researchers report that the agent was well tolerated at all doses 90 percent of patients experienced only grade I adverse events.
AME-133v appears to be capable of binding with high specificity to cell-surface antigens, resulting in targeted killing of malignant cells, relative sparing of normal tissues, and low toxicity, Forero said.
Promising clinical activity of an NAB paclitaxel plus gemcitabine combination in a disease-specific phase I trial in patients with advanced pancreatic cancer: Abstract 4179
Late-breaking data will be presented at the meeting.
Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment: Abstract 1210
Researchers from the Sanford School of Medicine at The University of South Dakota have demonstrated that mifepristone prevents regrowth of ovarian cancer cells that survive standard chemotherapy.
Utilizing a cell culture system, our work provides evidence that giving mifepris
'/>"/>
| Contact: Staci Vernick Goldberg Staci.goldberg@aacr.org 267-646-0616 American Association for Cancer Research Source:Eurekalert |
Related medicine news :
1. New review suggests caution on drugs to raise good cholesterol
2. Can cancer drugs combine forces?
3. Study provides hope that some transplant patients could live free of antirejection drugs
4. Study provides hope that some transplant patients could live free of anti-rejection drugs
5. RA Drugs Linked to Slight Skin Cancer Risk
6. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
7. Rock N Roll: Sex, Drugs and an Early Exit
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
10. Are Bargaining Groups Hired by Independent Drugstores Causing Payment Delays to Pharmacies?
11. 2 drugs equally effective for heart patients undergoing angioplasty, Mayo study finds
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |